Introducing MOAT - the BIOIO platform
MOAT (mechanism of action technologies) is a MoA-driven clinical indication prediction engine. MOAT combines both experimental and computational approaches.
All -omic approaches aren’t created equal
We deploy multi-omics, but based on two decades of experience, cell fitness based, unbiased genome-wide screening is the gold standard for establishing a small molecule’s MoA. Cell fitness (i.e., cell counting) is the only -omic phenotype that creates faithful signal to noise amplification. It’s the key differentiator from all other -omic techniques, be they genetic or biochemical. Importantly, the 2nd generation of the MOAT platform, MOAT 2.0, is now capable of performing the genomic screens virtually. These AI-generated predictions are highly accurate, thereby eliminating considerable time and cost in doing experiments.
The strengths of our approach are two-fold
First, ensuring an accurate understanding of a small molecule’s MoA is vital to establishing contexts in which it might be effective and what its liabilities might be. For example, in cancer, therapies are often used in combinations. Being precise about what each therapy uniquely targets is what enables strong synergies. The second strength of our MoA-led approach is that we ensure the compounds we advance are bona fide gerotherapies. A gerotherapy is a drug that addresses an underlying core aging mechanism. Because aging is the #1 risk factor for most diseases, a gerotherapy-first approach ensures a pipeline in a pill - where each asset can be used in multiple clinical indications. Both aspects of the MOAT platform ensure we are focused on drug efficacy, which is a main reason therapies fail.
Lipids are core components of the hallmarks of aging
BIOIO-1xx1 and BIOIO-2001 act on lipid metabolism. They both impinge on multiple hallmarks of aging, allowing a non-reductionist approach for developing gerotherapeutics.
BIOIO's scientific background
September 15, 2024
BIOIO validates its in silico Gene2Drug MOAT module in models of Rheumatoid arthritis. MOAT identified a chemical mimic of IKBz inhibition (Pubmed: 39279148).
February 6, 2024
BIOIO assists WashU colleagues in characterizing the MoA of a novel autoimmune drug. (PMID: 38319963)
January 19, 2023
BIOIO publishes on the MoA and in vivo validation of BIOIO-1001.
May 20, 2020
BIOIO publishes in vivo validation of the bona fide longevity drug, bisphosphonates, in Science Translational Medicine.
May 1, 2020
BIOIO was funded with a STTR NIH grant for MOAT (R41GM137625).
April 14, 2020
BIOIO posts foundational work that led to BIOIO-2001 on BioRxiv. It identifies sphingolipid biosynthesis as a common MoA of many widely prescribed drugs.
February 10, 2020
BIOIO partners with SPARC (Sun Pharma) to use BIOIO’s MOAT platform for oncology drug development.
September 16, 2019
BIOIO was inaugurally funded with a fast track STTR NIH grant based on BIOIO-1001 (R42DK121652).
August 19, 2019
BIOIO posts its Omniphenotype manuscript to BioRxiv. This is the key conceptual framework for MOAT.
BIOIO's scientific background
September 15, 2024
BIOIO validates its in silico Gene2Drug MOAT module in models of Rheumatoid arthritis. MOAT identified a chemical mimic of IKBz inhibition (Pubmed: 39279148).
February 6, 2024
BIOIO assists WashU colleagues in characterizing the MoA of a novel autoimmune drug. (PMID: 38319963)
January 19, 2023
BIOIO publishes on the MoA and in vivo validation of BIOIO-1001.
May 20, 2020
BIOIO publishes in vivo validation of the bona fide longevity drug, bisphosphonates, in Science Translational Medicine.
May 1, 2020
BIOIO was funded with a STTR NIH grant for MOAT (R41GM137625).
April 14, 2020
BIOIO posts foundational work that led to BIOIO-2001 on BioRxiv. It identifies sphingolipid biosynthesis as a common MoA of many widely prescribed drugs.
February 10, 2020
BIOIO partners with SPARC (Sun Pharma) to use BIOIO’s MOAT platform for oncology drug development.
September 16, 2019
BIOIO was inaugurally funded with a fast track STTR NIH grant based on BIOIO-1001 (R42DK121652).
August 19, 2019
BIOIO posts its Omniphenotype manuscript to BioRxiv. This is the key conceptual framework for MOAT.
